-
Recruiting
NCT NCT06467617
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Not yet reported
Beijing Chest Hospital, Capital Medical University
35 participants
Est. completion 2027-03-01
1 site
Stand-alone
Other conditions: Non Small Cell Lung Cancer
View official trial listing →
-
Recruiting
NCT NCT06738758
Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
Yun Dai Chen
6000 participants
Est. completion 2027-12-31
1 site
Other conditions: Acute Coronary Syndromes
View official trial listing →
-
Recruiting
NCT NCT06902740
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
Not yet reported
Peking Union Medical College Hospital
300 participants
Est. completion 2028-12-31
19 sites
Stand-alone
Other conditions: Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
View official trial listing →
-
Recruiting
NCT NCT07002476
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
Not yet reported
Shanghai East Hospital
978 participants
Est. completion 2027-06-01
1 site
Stand-alone
Cardiovascular disease
View official trial listing →
-
Not yet recruiting
NCT NCT07062328
A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC
Not yet reported
Sun Yat-sen University
39 participants
Est. completion 2028-04-20
Stand-alone
Other conditions: Biliary Tract Carcinoma
View official trial listing →
-
Not yet recruiting
NCT NCT07119918
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis
Not yet reported
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
5276 participants
Est. completion 2029-12-01
1 site
Stand-alone
Other conditions: Symptomatic Intracranial Atherosclerotic Stenosis
View official trial listing →
-
Not yet recruiting
NCT NCT07290699
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
Not yet reported
Second Affiliated Hospital of Nanchang University
2442 participants
Est. completion 2028-08-30
Stand-alone
Cardiovascular disease
View official trial listing →
-
Not yet recruiting
NCT NCT07373847
Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia
Not yet reported
Xiangya Hospital of Central South University
40 participants
Est. completion 2027-08-30
Stand-alone
Other conditions: Plaque Psoriasis
View official trial listing →
-
Not yet recruiting
NCT NCT07466251
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
Not yet reported
Peking Union Medical College Hospital
1212 participants
Est. completion 2029-12-31
19 sites
Stand-alone
Cardiovascular disease
Other conditions: Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
View official trial listing →
-
Not yet recruiting
NCT NCT07567326
Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
Not yet reported
Peking University Cancer Hospital & Institute
78 participants
Est. completion 2030-12
Stand-alone
Other conditions: Non Small Cell Lung Cancer
View official trial listing →
-
Not yet recruiting
NCT NCT07605130
Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2x2 Factorial, Randomized, Parallel-Group, Multicenter Trial
Not yet reported
Peking Union Medical College Hospital
440 participants
Est. completion 2029-07-31
1 site
Stand-alone
Other conditions: Intracranial Arteriosclerosis, Cognitive Impairment
View official trial listing →
-
Not yet recruiting
NCT NCT07674368
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
Not yet reported
Hunan Cancer Hospital
29 participants
Est. completion 2028-08-01
1 site
Stand-alone
Other conditions: ALK Fusion-positive Non-small Cell Lung Cancer
View official trial listing →
-
Not yet recruiting
NCT NCT07951320
Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors
Not yet reported
Xiangya Hospital of Central South University
100 participants
Est. completion 2028-09-30
7 sites
Stand-alone
Other conditions: Plaque Psoriasis, Dyslipidemia
View official trial listing →